153 related articles for article (PubMed ID: 28344890)
1. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL; Mohapatra SR; Blanco Cabañes S; Adam I; Somarribas Patterson LF; Berdel B; Kahloon M; Thürmann L; Loth S; Heilmann K; Weichenhan D; Mücke O; Heiland I; Wimberger P; Kuhlmann JD; Kellner KH; Schott S; Plass C; Platten M; Gerhäuser C; Trump S; Opitz CA
Oncoimmunology; 2017; 6(2):e1274477. PubMed ID: 28344890
[TBL] [Abstract][Full Text] [Related]
2. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2, 3-dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer.
Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ogata Y; Eto K; Hiyoshi Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Cancer Sci; 2019 Jun; 110(6):1863-1871. PubMed ID: 31012515
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
[TBL] [Abstract][Full Text] [Related]
5. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal Regulation Between Indoleamine 2,3-Dioxigenase 1 and Notch1 Involved in Radiation Response of Cervical Cancer Stem Cells.
Low HY; Lee YC; Lee YJ; Wang HL; Chen YI; Chien PJ; Li ST; Chang WW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545442
[TBL] [Abstract][Full Text] [Related]
7. GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Wei JL; Wu SY; Yang YS; Xiao Y; Jin X; Xu XE; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281987
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
10. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
Yan Z; Gao S; Wu X; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
14. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
16. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
17. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: potential therapeutic use in autoimmune diseases.
Xue ZT; Sjögren HO; Salford LG; Widegren B
Mol Immunol; 2012 Jun; 51(2):101-11. PubMed ID: 22424783
[TBL] [Abstract][Full Text] [Related]
18. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan deficiency induced by indoleamine 2,3-dioxygenase 1 results in glucose transporter 1-dependent promotion of aerobic glycolysis in pancreatic cancer.
Liang H; Zhan J; Chen Y; Xing Z; He ZNT; Liu Y; Li X; Chen Y; Li Z; Kuang C; Yang D; Yang Q
MedComm (2020); 2024 May; 5(5):e555. PubMed ID: 38706741
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Wang XX; Sun SY; Dong QQ; Wu XX; Tang W; Xing YQ
Medchemcomm; 2019 Oct; 10(10):1740-1754. PubMed ID: 32055299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
